Since targeting the surface antigen CEA has been shown to be effective for PIT in orthotopic pancreatic cancer models, it may also be a useful target for the use of PIT in colorectal cancer as CEA is overexpressed in almost all colorectal cancers [7, 8]. This evidence concerns the gene CEACAM5 and pancreatic neoplasm.